HLB Life Science Co., Ltd. (KOSDAQ:067630)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,830.00
-55.00 (-1.42%)
Mar 3, 2026, 3:30 PM KST
-64.07%
Market Cap 466.67B
Revenue (ttm) 114.33B
Net Income (ttm) -178.33B
Shares Out 121.85M
EPS (ttm) -1,434.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 975,032
Average Volume 556,352
Open 3,800.00
Previous Close 3,885.00
Day's Range 3,700.00 - 4,100.00
52-Week Range 3,105.00 - 11,940.00
Beta -0.06
RSI 41.12
Earnings Date Mar 19, 2026

About HLB Life Science

HLB Life Science Co., Ltd. develops and manufactures in vitro diagnostic medical devices and quasi-drugs in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colon cancer, hepatocellular carcinoma, non-small cell lung cancer, breast cancer, mesothelioma, renal cell carcinoma, and neuroendocrine tumors; and Pyrotinib, an anticancer drug that inhibits the proliferation, division, and survival of cancer cells. In addition, the co... [Read more]

Sector Utilities
Founded 1998
Employees 153
Stock Exchange KOSDAQ
Ticker Symbol 067630
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.